Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024
RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.
Roche Group Sales In Q3, 9M Rise; Confirms FY24 Outlook
Swiss drug major Roche Group (RHHBY) reported Wednesday that its third-quarter Group sales increased 6 percent from last year on a
Roche Confirms Profit Forecast as Sales Beat Estimates
Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and hemophilia injection Hemlibra lifted third-quarter sales above analysts’ expectations.
Roche Q3 sales advance by forex-adj 9%, beating market view
Roche on Wednesday said that third-quarter sales gained a currency-adjusted 9% to 15.14 billion Swiss francs ($17.46 billion).
Roche reaffirms 2024 outlook after Q3 beat
Roche Holding (RHHBF) reaffirms full-year sales and earnings outlook after its Q3 results exceeded Street forecasts. Read more here.
1d
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...
FiercePharma
1d
Roche's Vabysmo will rise above Eylea biosim threat, exec says, as DMD gene therapy Elevidys delivers sales surprise
By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...
Pharmaceutical Technology
1d
AAO 2024: NMA reveals Vabysmo’s superior CST improvement over Eylea HD
This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.
clinicaltrialsarena
3d
Roche reports topline data from trial of Vabysmo for diabetic macular oedema
Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular ...
Investor's Business Daily on MSN
1d
Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations
Roche stock jumped Wednesday after the pharma giant reported light third-quarter sales but kept its 2024 outlook.
BioSpace
1d
Roche Beats Q3 Sales Estimates as CEO Voices Opposition to Novo Holdings’ Catalent Buyout
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...
pharmaphorum
3d
Roche trial confirms Vabysmo efficacy in minorities
A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African ...
Business Wire
5d
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...
The Pharma Letter
3d
Roche’s Vabysmo improved vision in underrepresented populations
Swiss pharma giant Roche (ROG: SIX) on Friday released positive top-line one-year results from the open-label, single-arm ...
manilatimes
6d
Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Roche
Genentech
Race and ethnicity in the United States Census
Ocrelizumab
Feedback